Abstract:Allo-HSCT is a potentially curative therapy for many hematological malignancies, the basis of which is graft-versus-leukemia (GVL) effect. However, acute graft-versus-host disease (GVHD) is responsible for 15% to 40% of mortality and is the major cause of morbidity after transplantation. Therefore, separation of GVHD and GVL partially or completely could improve the transplant outcomes. This study focuses on the effects of G-CSF on T cells in peripheral blood stem cell grafts and bone marrow grafts and its mechanisms after in vivo G-CSF application. The separation of GVHD and GVL effect and the mechanisms of which after in vivo G-CSF and interleukin-11 (IL-11) treatment of healthy donors were investigated. The main contributions of this research are listed as follows: (1) Immune tolerance of T cells was induced simultaneously in peripheral blood stem cell grafts and bone marrow grafts after in vivo G-CSF application; (2) T cell hyporesponsiveness and polarization of T cells from Th1 to Th2 were maintained after mixture of G-CSF-mobilized peripheral blood grafts (G-PB) and G-CSF-primed bone marrow grafts (G-BM) according to different proportions in vitro; (3) Treating donor with G-CSF and IL-11 decreased GVHD and retained GVL effect; (4) The incidence of acute GVHD was decreased after Allo-HSCT using G-PB and G-BM as allografts; (5) In combination with other techniques, the HLA barriers were overcomed using G-PB and G-BM as allografts; (6) The incidences of acute GVHD were significantly decreased and the GVL effects were retained or enhanced in relapsed patients after treatment by G-CSF-mobilized peripheral blood graft infusion compared with those received steady-state peripheral blood lymphocyte infusion, indicating that GVHD and GVL could be partially separated in clinical settings. Based on our results, we would conclude that the issues on the deficiency of donors are resolved, and novel strategies offered for the prophylaxis and treatment of patients with hematological malignancies who relapse after Allo-HSCT. Further studies on the mechanism of the separation of GVL and GVHD are warranted.

Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation

Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD

Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease

Immune Tolerance Induced by Cytokines in Allogeneic Hematopoietic Stem Cell Transplantation

Haploidentical SCT: the Mechanisms Underlying the Crossing of HLA Barriers.

Graft-versus-Host Disease Modulation by Innate T Cells

How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia

The impact of regulatory T cells on the graft-versus-leukemia effect

A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications

Immunomodulation and Pharmacological Strategies in the Treatment of Graft-Versus-host Disease

Future directions in haploidentical hematopoietic stem cell transplantation

Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Advances in the treatment of graft-versus-host disease with immunomodulatory cells

Haploidentical Hematopoietic Transplantation Without T-cell Depletion: Current Status and Future Perspectives.

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy

Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease

Haploidentical Transplants with a G-CSF/ATG-based Protocol: Experience from China

Regulatory T-Cell Therapy for Graft-versus-host Disease.

International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant

Cellular Mechanism for Granulocyte-Colony Stimulating Factor in the Prevention of Graft-Versus-host Disease in Combined Bone Marrow and Peripheral Blood Transplantation for Hematological Malignancies: the Composition in Collection